32 Biosciences is a GI-focused biotechnology company advancing first-in-class upstream therapeutics centered on the GI mucosal-immune system.
We believe an important therapeutic opportunity exists earlier in GI disease biology, before infection or inflammatory amplification.
Our Lead Therapeutic:
CS-0003 is a first-in-class Mucosal-Immune Modulator designed to stabilize the GI mucosal barrier, suppress stress-induced bacterial virulence signaling, and support balanced mucosal-immune responses.
Broader Potential:
Related upstream biology may also be relevant in inflammatory bowel disease, anastomotic leak, recurrent C. difficile infection, sepsis, colon cancer recurrence, and chemotherapy-related GI toxicities.
Functional Biology Supporting Therapeutic Development
The GB Discovery & Functional Biology Platform uses functional metabolomics to measure gut microbial ecosystem activity and may support biomarkers, patient stratification, partnerships, longitudinal data, and
discovery.
Our Scientific Foundation
Our work builds on decades of research in GI mucosal biology, bacterial virulence, host-microbe relationships, and functional metabolomics.
32 Biosciences was founded to address a critical gap in gastrointestinal medicine: today’s tools and therapies do not address the biology that drives GI disease. Surgical infections, chronic inflammation, and recurrent conditions arise when the gut mucosal-immune barrier becomes destabilized — yet existing interventions do not restore this barrier or measure gut microbiome function.
Our team came together with a unified vision: to pioneer solutions that restore and protect the gut mucosal-immune system and make the functional state of the gut measurable, actionable, and central to patient care.
Our mission is to restore gut mucosal-immune health and deliver metabolomic and data-driven insights that accelerate therapeutic discovery, improve patient outcomes, and transform standards of care across high-burden GI diseases.
We envision a future where:
Above all, we aim to deliver solutions that provide predictability, protection, and better outcomes at the moments patients need them most.
Our name, 32 Biosciences (pronounced three squared), reflects our commitment to exponential progress – bringing multidisciplinary innovation together to advance gut mucosal-immune science.